美股市場個股詳情
EXEL 伊克力西斯
- 36.020
- +1.520+4.41%
收盤價 01/10 16:00 (美東)
- 36.150
- +0.130+0.36%
盤後 20:01 (美東)
102.87億總市值23.24市盈率TTM
36.190最高價34.100最低價312.06萬股成交量34.250今開34.500昨收1.11億成交額1.30%換手率55.42市盈率(靜)2.86億總股本36.97052周最高4.52市淨率86.68億流通值20.01552周最低--股息TTM2.41億流通股50.500歷史最高--股息率TTM6.06%振幅1.260歷史最低35.562平均價1股每手
關於伊克力西斯公司
Exelixis 是一家發現、開發和商業化癌症治療的生物製藥公司， 其先導分子 cabozantinib 以 Cometriq 爲名用於治療轉移性甲狀腺髓樣癌患者，以 Cabometyx 爲名用於治療腎癌和肝癌。 Exelixis 及其合作伙伴羅氏也將 Cotellic 推向了治療黑色素瘤的市場。
公司介紹
公司代碼EXEL
公司名稱伊克力西斯
上市日期2000/04/11
發行價格13.00
成立日期1994
CEODr. Michael M. Morrissey, PhD
所屬市場納斯達克
員工數量1310
年結日12-29
公司地址1851 Harbor Bay Parkway
城市Alameda
省份加利福尼亞州
國家美國
郵編94502
電話1-650-837-7000
董事高管
- 姓名
- 職務
- 年薪
- Dr. Michael M. Morrissey, PhD
- Director, President and Chief Executive Officer
- 1642.33萬
- Dr. Amy C. Peterson, M.D.
- Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
- 736.78萬
- Christopher J. Senner
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 494.76萬
- Dr. Dana T. Aftab, PhD
- Chief Scientific Officer and Executive Vice President, Discovery and Translational Research
- 565.31萬
- Patrick J. Haley
- Executive Vice President, Commercial
- --
- Jeffrey J. Hessekiel
- Executive Vice President, General Counsel and Secretary
- 456.27萬
- Dr. Stelios Papadopoulos,PhD
- Chairman of the Board
- 52.00萬
- Dr. Sue Gail Eckhardt, M.D.
- Director
- --
- Dr. Mary C. Beckerle, PhD
- Director
- --
- Tomas J. Heyman
- Independent Director
- 71.62萬
- Dr. George H. Poste, D.V.M.,F.R.S.,PhD
- Independent Director
- 48.22萬
- Jack L. Wyszomierski, M.S.
- Independent Director
- 49.10萬
- Julie Anne Smith
- Independent Director
- 49.09萬
- David E. Johnson
- Independent Director
- 71.87萬
- Robert Oliver, M.B.A.
- Independent Director
- 71.74萬
- Dr. Maria C. Freire, PhD
- Independent Director
- 48.87萬
熱議
美股
綜合熱度
股票代碼
最新價
升跌幅
暫無數據